Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Nigel Shankley

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Living Beings

Physiology

Competitive Binding

Chemicals & Drugs

Concepts & Ideas

Drug Dose-Response Relationship

Anatomy

Phenomena

Muscle Contraction

Procedures

Radioligand Assay

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Rosen Mark D; Woods Craig R; Goldberg Steven D; Hack Michael D; Bounds A Dawn; Yang Young; Wagaman Pamela C; Phuong Victor K; Ameriks Angela P; Barrett Terrance D; Kanelakis Kimon C; Chang Jui; Shankley Nigel P; Rabinowitz Michael H
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.
Pippel Marna; Boyce Kristen; Venkatesan Hariharan; Phuong Victor K; Yan Wen; Barrett Terrance D; Lagaud Guy; Li Lina; Morton Magda F; Prendergast Clodagh; Wu Xiaodong; Shankley Nigel P; Rabinowitz Michael H
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
Pippel Marna; Allison Brett D; Phuong Victor K; Li Lina; Morton Magda F; Prendergast Clodagh; Wu Xiaodong; Shankley Nigel P; Rabinowitz Michael H
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Nigel Shankley (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Rosen Mark D; Woods Craig R; Goldberg Steven D; Hack Michael D; Bounds A Dawn; Yang Young; Wagaman Pamela C; Phuong Victor K; Ameriks Angela P; Barrett Terrance D; Kanelakis Kimon C; Chang Jui; Shankley Nigel P; Rabinowitz Michael H
Discovery of the first known small-molecule inhibitors of heme-regulated eukaryotic initiation factor 2alpha (HRI) kinase.
Bioorganic & medicinal chemistry letters 2009;19(23):6548-51.
2009: Pippel Marna; Boyce Kristen; Venkatesan Hariharan; Phuong Victor K; Yan Wen; Barrett Terrance D; Lagaud Guy; Li Lina; Morton Magda F; Prendergast Clodagh; Wu Xiaodong; Shankley Nigel P; Rabinowitz Michael H
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy.
Bioorganic & medicinal chemistry letters 2009;19(22):6376-8.
2009: Pippel Marna; Allison Brett D; Phuong Victor K; Li Lina; Morton Magda F; Prendergast Clodagh; Wu Xiaodong; Shankley Nigel P; Rabinowitz Michael H
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
Bioorganic & medicinal chemistry letters 2009;19(22):6373-5.
2009: Kanelakis Kimon C; Palomino Heather L; Li Lina; Wu Jiejun; Yan Wen; Rosen Mark D; Rizzolio Michele C; Trivedi Meghana; Morton Magda F; Yang Young; Venkatesan Hariharan; Rabinowitz Michael H; Shankley Nigel P; Barrett Terrance D
Characterization of a robust enzymatic assay for inhibitors of 2-oxoglutarate-dependent hydroxylases.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2009;14(6):627-35.
2008: Barrett T D; Yan W; Freedman J M; Lagaud G J; Breitenbucher J G; Shankley N P
Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction.
British journal of pharmacology 2008;153(8):1650-8.
2008: Rosen Mark D; Hack Michael D; Allison Brett D; Phuong Victor K; Woods Craig R; Morton Magda F; Prendergast Clodagh E; Barrett Terrance D; Schubert Carsten; Li Lina; Wu Xiaodong; Wu Jiejun; Freedman Jamie M; Shankley Nigel P; Rabinowitz Michael H
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis.
Bioorganic & medicinal chemistry 2008;16(7):3917-25.
2007: Woods Craig R; Hack Michael D; Allison Brett D; Phuong Victor K; Rosen Mark D; Morton Magda F; Prendergast Clodagh E; Barrett Terrance D; Shankley Nigel P; Rabinowitz Michael H
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands.
Bioorganic & medicinal chemistry letters 2007;17(24):6905-9.
2007: Gomez Laurent; Hack Michael D; McClure Kelly; Sehon Clark; Huang Liming; Morton Magda; Li Lina; Barrett Terrance D; Shankley Nigel; Breitenbucher J Guy
SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.
Bioorganic & medicinal chemistry letters 2007;17(23):6493-8.
2007: Bhattacharya Anindya; Scott Brian P; Nasser Nadia; Ao Hong; Maher Michael P; Dubin Adrienne E; Swanson Devin M; Shankley Nigel P; Wickenden Alan D; Chaplan Sandra R
Pharmacology and antitussive efficacy of 4-(3-trifluoromethyl-pyridin-2-yl)-piperazine-1-carboxylic acid (5-trifluoromethyl-pyridin-2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs.
The Journal of pharmacology and experimental therapeutics 2007;323(2):665-74.
2007: Morton Magda F; Barrett Terrance D; Yan Wen; Freedman Jamie M; Lagaud Guy; Prendergast Clodagh E; Moreno Veronica; Pyati Jayashree; Figueroa Katherine; Li Lina; Wu Xiaodong; Rizzolio Michele; Breitenbucher James G; McClure Kelly; Shankley Nigel P
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
The Journal of pharmacology and experimental therapeutics 2007;323(2):562-9.
2007: Lagaud Guy J; Young Andy; Acena Auzon; Morton Magda F; Barrett Terrance D; Shankley Nigel P
Obestatin reduces food intake and suppresses body weight gain in rodents.
Biochemical and biophysical research communications 2007;357(1):264-9.
2007: Harper E A; Shankley N P; Black J W
Correlation of apparent affinity values from H3-receptor binding assays with apparent affinity (pKapp) and intrinsic activity (alpha) from functional bioassays.
British journal of pharmacology 2007;151(1):128-43.
2007: Gerskowitch V P; Hodge J; Hull R A D; Shankley N P; Kalindjian S B; McEwen J; Black J W
Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist.
British journal of clinical pharmacology 2007;63(5):618-22.
2006: Shankley Nigel; Cox Bryan F; Brunton Laurence L
Who's afraid of ligand-macromolecule interactions in complex physiological systems?
Molecular interventions 2006;6(6):296-9.
2006: Allison Brett D; Phuong Victor K; McAtee Laura C; Rosen Mark; Morton Magda; Prendergast Clodagh; Barrett Terry; Lagaud Guy; Freedman Jamie; Li Lina; Wu Xiaodong; Venkatesan Hariharan; Pippel Marna; Woods Craig; Rizzolio Michèle C; Hack Michael; Hoey Kenway; Deng Xiaohu; King Christopher; Shankley Nigel P; Rabinowitz Michael H
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
Journal of medicinal chemistry 2006;49(21):6371-90.
2006: Jones Neil A; Morton Magda F; Prendergast Clodagh E; Powell Garth L; Shankley Nigel P; Hollingsworth Simon J
Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitro.
Regulatory peptides 2006;136(1-3):109-16.
2006: Freedman Jamie M; Barrett Terrance D; Shankley Nigel P
A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat.
Journal of pharmacological and toxicological methods 2006;54(1):36-41.
2006: Prendergast Clodagh E; Morton Magda F; Figueroa Katherine W; Wu Xiaodong; Shankley Nigel P
Species-dependent smooth muscle contraction to Neuromedin U and determination of the receptor subtypes mediating contraction using NMU1 receptor knockout mice.
British journal of pharmacology 2006;147(8):886-96.
2006: McClure Kelly; Hack Michael; Huang Liming; Sehon Clark; Morton Magda; Li Lina; Barrett Terrance D; Shankley Nigel; Breitenbucher J Guy
Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity.
Bioorganic & medicinal chemistry letters 2006;16(1):72-6.
2006: Sehon Clark; McClure Kelly; Hack Michael; Morton Magda; Gomez Laurent; Li Lina; Barrett Terrance D; Shankley Nigel; Breitenbucher J Guy
Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity.
Bioorganic & medicinal chemistry letters 2006;16(1):77-80.
2005: Galindo Jose; Jones Neil; Powell Garth L; Hollingsworth Simon J; Shankley Nigel
Advanced qRT-PCR technology allows detection of the cholecystokinin 1 receptor (CCK1R) expression in human pancreas.
Pancreas 2005;31(4):325-31.
2005: Buck Ildiko M; Black James W; Cooke Tracey; Dunstone David J; Gaffen John D; Griffin Eric P; Harper Elaine A; Hull Robert A D; Kalindjian S Barret; Lilley Elliot J; Linney Ian D; Low Caroline M R; McDonald Iain M; Pether Michael J; Roberts Sonia P; Shankley Nigel P; Shaxted Mark E; Steel Katherine I M; Sykes David A; Tozer Matthew J; Watt Gillian F; Walker Martin K; Wright Laurence; Wright Paul T
Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists.
Journal of medicinal chemistry 2005;48(22):6803-12.
2005: Low Caroline M R; Buck Ildiko M; Cooke Tracey; Cushnir Julia R; Kalindjian S Barret; Kotecha Atul; Pether Michael J; Shankley Nigel P; Vinter J G; Wright Laurence
Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists.
Journal of medicinal chemistry 2005;48(22):6790-802.
2005: Morton Magda F; Liu Pei-Qi; Reik Andreas; de la Rosa Ragan; Mendel Matthew; Li Xiao-Yong; Case Casey; Pabo Carl; Moreno Veronica; Pyati Jayashree; Shankley Nigel P
Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors.
Regulatory peptides 2005;129(1-3):227-32.
2005: Morton Magda Francesca; Pyati Jayashree; Dai Heng; Li Lina; Moreno Veronica; Shankley Nigel Paul
Molecular cloning, expression and pharmacological characterization of the canine cholecystokinin 1 receptor.
British journal of pharmacology 2005;145(3):374-84.
2005: Bachar Ofir; Rose Andrew C; Adner Mikael; Wang Xudong; Prendergast Clodagh E; Kempf Ashley; Shankley Nigel P; Cardell Lars-Olaf
TNF alpha reduces tachykinin, PGE2-dependent, relaxation of the cultured mouse trachea by increasing the activity of COX-2.
British journal of pharmacology 2005;144(2):220-30.
2004: Liu Pei-Qi; Morton Magda F; Reik Andreas; de la Rosa Ragan; Mendel Matthew C; Li Xiao-Yong; Case Casey C; Pabo Carl O; Moreno Veronica; Kempf Ashley; Pyati Jayashree; Shankley Nigel P
Cell lines for drug discovery: elevating target-protein levels using engineered transcription factors.
Journal of biomolecular screening : the official journal of the Society for Biomolecular Screening 2004;9(1):44-51.
2003: Morton M F; Harper E A; Tavares I A; Shankley N P
Pharmacological comparison of the alternatively spliced short and long CCK2 receptors.
British journal of pharmacology 2003;140(1):218-24.
2002: Adner Mikael; Rose Andrew C; Zhang Yaping; Swärd Karl; Benson Mikael; Uddman Rolf; Shankley Nigel P; Cardell Lars-Olaf
An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFalpha up-regulates 5-HT(2A)-mediated contraction.
British journal of pharmacology 2002;137(7):971-82.
2002: Morton M F; Harper E A; Tavares I A; Shankley N P
Pharmacological evidence for putative CCK(1) receptor heterogeneity in human colon smooth muscle.
British journal of pharmacology 2002;136(6):873-82.
2002: Morton M F; Welsh N J; Tavares I A; Shankley N P
Pharmacological characterization of cholecystokinin receptors mediating contraction of human gallbladder and ascending colon.
Regulatory peptides 2002;105(1):59-64.
2001: Adner M; Shankley N; Edvinsson L
Evidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ET(B) receptors.
British journal of pharmacology 2001;133(6):927-35.
2001: Harper E A; Lovenberg T W; Shankley N P; Black J W
Comparison of ligand affinity values at the recombinant human H3 receptor and at H3 receptor(s) of human cingulate cortex.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2001;50 Suppl 2():S106-7.
2001: Kalindjian S B; Dunstone D J; Low C M; Pether M J; Roberts S P; Tozer M J; Watt G F; Shankley N P
Nonpeptide cholecystokinin-2 receptor agonists.
Journal of medicinal chemistry 2001;44(8):1125-33.
2000: Low C M; Black J W; Broughton H B; Buck I M; Davies J M; Dunstone D J; Hull R A; Kalindjian S B; McDonald I M; Pether M J; Shankley N P; Steel K I
Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists.
Journal of medicinal chemistry 2000;43(19):3505-17.
2000: Linney I D; Buck I M; Harper E A; Kalindjian S B; Pether M J; Shankley N P; Watt G F; Wright P T
Design, synthesis, and structure-activity relationships of novel non-imidazole histamine H(3) receptor antagonists.
Journal of medicinal chemistry 2000;43(12):2362-70.
2000: Prins N H; Shankley N P; Welsh N J; Briejer M R; Lefebvre R A; Akkermans L M; Schuurkes J A
An improved in vitro bioassay for the study of 5-HT(4) receptors in the human isolated large intestinal circular muscle.
British journal of pharmacology 2000;129(8):1601-8.
2000: Prendergast C E; Shankley N P; Black J W
Negative inotropic effects of isoprenaline on isolated left atrial assays from aged transgenic mice with cardiac over-expression of human beta(2)-adrenoceptors.
British journal of pharmacology 2000;129(7):1285-8.
1999: Harper E A; Shankley N P; Black J W
Characterization of the binding of [3H]-clobenpropit to histamine H3-receptors in guinea-pig cerebral cortex membranes.
British journal of pharmacology 1999;128(4):881-90.
1999: Harper E A; Shankley N P; Black J W
Evidence that histamine homologues discriminate between H3-receptors in guinea-pig cerebral cortex and ileum longitudinal muscle myenteric plexus.
British journal of pharmacology 1999;128(3):751-9.
1999: Tozer M J; Harper E A; Kalindjian S B; Pether M J; Shankley N P; Watt G F
From histamine to imidazolylalkyl-sulfonamides: the design of a novel series of histamine H3-receptor antagonists.
Bioorganic & medicinal chemistry letters 1999;9(13):1825-30.
1999: Harper E A; Shankley N P; Black J W
Characterization of the binding of a novel radioligand to CCKB/gastrin receptors in membranes from rat cerebral cortex.
British journal of pharmacology 1999;126(6):1504-12.
1999: Harper E A; Griffin E P; Shankley N P; Black J W
Analysis of the behaviour of selected CCKB/gastrin receptor antagonists in radioligand binding assays performed in mouse and rat cerebral cortex.
British journal of pharmacology 1999;126(6):1496-503.
1998: Meester B J; Shankley N P; Welsh N J; Meijler F L; Black J W
Pharmacological analysis of the activity of the adenosine uptake inhibitor, dipyridamole, on the sinoatrial and atrioventricular nodes of the guinea-pig.
British journal of pharmacology 1998;124(4):729-41.
1998: Meester B J; Shankley N P; Welsh N J; Wood J; Meijler F L; Black J W
Pharmacological classification of adenosine receptors in the sinoatrial and atrioventricular nodes of the guinea-pig.
British journal of pharmacology 1998;124(4):685-92.
1997: Hill S J; Ganellin C R; Timmerman H; Schwartz J C; Shankley N P; Young J M; Schunack W; Levi R; Haas H L
International Union of Pharmacology. XIII. Classification of histamine receptors.
Pharmacological reviews 1997;49(3):253-78.
1996: Hills D M; Gerskowitch V P; Roberts S P; Welsh N J; Shankley N P; Black J W
Pharmacological analysis of the CCKB/gastrin receptors mediating pentagastrin-stimulated gastric acid secretion in the isolated stomach of the immature rat.
British journal of pharmacology 1996;119(7):1401-10.
1996: Van der Graaf P H; Shankley N P; Black J W
Analysis of the action of idazoxan calls into question the reliability of the rat isolated small mesenteric artery assay as a predictor for alpha 1-adrenoceptor-mediated pressor activity.
Naunyn-Schmiedeberg's archives of pharmacology 1996;354(3):389-92.
1996: Roberts S P; Harper E A; Watt G F; Gerskowitch V P; Hull R A; Shankley N P; Black J W
Analysis of the variation in the action of L-365,260 at CCKB/gastrin receptors in rat, guinea-pig and mouse isolated gastric tissue assays.
British journal of pharmacology 1996;118(7):1779-89.
1996: Harper E A; Roberts S P; Shankley N P; Black J W
Analysis of variation in L-365,260 competition curves in radioligand binding assays.
British journal of pharmacology 1996;118(7):1717-26.
1996: Van der Graaf P H; Shankley N P; Black J W
Analysis of the effects of alpha 1-adrenoceptor antagonists on noradrenaline-mediated contraction of rat small mesenteric artery.
British journal of pharmacology 1996;118(5):1308-16.
1996: Van der Graaf P H; Shankley N P; Black J W
Analysis of the activity of alpha 1-adrenoceptor antagonists in rat aorta.
British journal of pharmacology 1996;118(2):299-310.
1995: Van der Graaf P H; Saxena P R; Shankley N P; Black J W
Exposure and characterization of the action of noradrenaline at dopamine receptors mediating endothelium-independent relaxation of rat isolated small mesenteric arteries.
British journal of pharmacology 1995;116(8):3237-42.
1995: Welsh N J; Shankley N P; Black J W
Application of a model to explore interspecies differences in acetylcholine M-receptor-stimulated gastric acid secretion.
British journal of pharmacology 1995;115(6):961-8.
1995: Prentice D J; Shankley N P; Black J W
Pharmacological analysis of the interaction between purinoceptor agonists and antagonists in the guinea-pig taenia caecum.
British journal of pharmacology 1995;115(4):549-56.
1995: Jenkinson D H; Barnard E A; Hoyer D; Humphrey P P; Leff P; Shankley N P
International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology.
Pharmacological reviews 1995;47(2):255-66.
1995: Black J W; Shankley N P
Drug receptors. Inverse agonists exposed.
Nature 1995;374(6519):214-5.
1995: Shankley N P; Watt G F; Black J W
Definition and localization of histamine H2 receptors.
European journal of clinical investigation 1995;25 Suppl 1():12-8.
1995: Bishop L A; Gerskowitch V P; Hull R A; Shankley N P; Black J W
The use of receptor desensitization to analyse CCKA and CCKB/gastrin receptors coupled to contraction in guinea-pig stomach muscle.
British journal of pharmacology 1995;114(2):339-48.
1994: Welsh N J; Shankley N P; Black J W
Comparative analysis of the vagal stimulation of gastric acid secretion in rodent isolated stomach preparations.
British journal of pharmacology 1994;112(1):93-6.
1993: Welsh N J; Shankley N P; Black J W
Comparative study of the control of basal acid output from rodent isolated stomachs.
British journal of pharmacology 1993;109(4):941-5.
1993: Hull R A; Shankley N P; Harper E A; Gerkowitch V P; Black J W
2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.
British journal of pharmacology 1993;108(3):734-40.
1992: Shankley N P; Welsh N J; Black J W
Histamine dependence of pentagastrin-stimulated gastric acid secretion in rats.
The Yale journal of biology and medicine 1992;65(6):613-9.
1992: Liu Y J; Shankley N P; Welsh N J; Black J W
Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action.
British journal of pharmacology 1992;106(2):233-41.
1992: Bishop L A; Gerskowitch V P; Hull R A; Shankley N P; Black J W
Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
British journal of pharmacology 1992;106(1):61-6.
1991: Durant P A; Shankley N P; Welsh N J; Black J W
Pharmacological analysis of agonist-antagonist interactions at acetylcholine muscarinic receptors in a new urinary bladder assay.
British journal of pharmacology 1991;104(1):145-50.
1990: Black J W; Shankley N P
Interpretation of agonist affinity estimations: the question of distributed receptor states.
Proceedings of the Royal Society of London. Series B, Containing papers of a Biological character. Royal Society (Great Britain) 1990;240(1299):503-18.
1988: Gerskowitch V P; Hull R A; Shankley N P
Nobel prize recognizes industrial scientists' contribution to pharmacology and medicine.
Trends in pharmacological sciences 1988;9(12):435-7.
1988: Shankley N P; Black J W; Ganellin C R; Mitchell R C
Correlation between log POCT/H2O and pKB estimates for a series of muscarinic and histamine H2-receptor antagonists.
British journal of pharmacology 1988;94(1):264-74.
1987: Trist D G; Leff P; Black J; Gerskowitch V P; Shankley N P
Resultant action of cimetidine in a cardiac adenylate cyclase assay: its elucidation by concentration-ratios analysis.
The Journal of pharmacology and experimental therapeutics 1987;243(3):1043-7.
1986: Black J W; Gerskowitch V P; Leff P; Shankley N P
Analysis of competitive antagonism when this property occurs as part of a pharmacological resultant.
British journal of pharmacology 1986;89(3):547-55.
1986: Black J W; Shankley N P
Pharmacological analysis of the inhibition by pirenzepine and atropine of vagal-stimulated acid secretion in the isolated stomach of the mouse.
British journal of pharmacology 1986;88(1):291-7.
1985: Black J W; Shankley N P
Pharmacological analysis of muscarinic receptors coupled to oxyntic cell secretion in the mouse stomach.
British journal of pharmacology 1985;86(3):601-7.
1985: Black J W; Leff P; Shankley N P
Pharmacological analysis of the pentagastrin-tiotidine interaction in the mouse isolated stomach.
British journal of pharmacology 1985;86(3):589-99.
1985: Black J W; Leff P; Shankley N P
Further analysis of anomalous pKB values for histamine H2-receptor antagonists on the mouse isolated stomach assay.
British journal of pharmacology 1985;86(3):581-7.
1985: Black J W; Shankley N P
Pharmacological analysis of the muscarinic receptors involved when McN-A 343 stimulates acid secretion in the mouse isolated stomach.
British journal of pharmacology 1985;86(3):609-17.
1985: Black J W; Shankley N P
The isolated stomach preparation of the mouse: a physiological unit for pharmacological analysis.
British journal of pharmacology 1985;86(3):571-9.
1985: Black J W; Gerskowitch V P; Leff P; Shankley N P
Pharmacological analysis of beta-adrenoceptor-mediated agonism in the guinea-pig, isolated, right atrium.
British journal of pharmacology 1985;84(3):779-85.
1985: Black J W; Leff P; Shankley N P; Wood J
An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation.
British journal of pharmacology 1985;84(2):561-71.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Nigel Shankley

Research Profile (preview)

Living Beings

Physiology

Chemicals & Drugs

Concepts & Ideas

Anatomy

Phenomena

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Nigel Shankley (preview)

All Publications